Olatec Therapeutics
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
800 5th Ave Apt 25D, New York, New York,...Website
www.olatec.comRevenue
<$5 MillionIndustry
About Olatec Therapeutics
Olatec is a privately held biopharmaceutical company focused on the clinical development of NLRP3 antagonist therapeutics aimed at treating a wide range of inflammatory diseases, including arthritis, heart failure, and various cancers. Their lead compound, dapansutrile, has shown clinical benefits in reducing systemic inflammation and has a favorable safety profile. With a robust pipeline of approximately 40 pharmaceutical candidates and a strong intellectual property portfolio, Olatec is positioned to make significant advancements in inflammation treatment. The company operates in the United States and Europe, leveraging a team of experienced management and international thought leaders in inflammation and immunology.Explore more
SIC Code 28,283NAICS Code 32,325Show moreOlatec Therapeutics Org Chart
Compare Similar Companies to Olatec Therapeutics
Compare insights from companies similar to Olatec Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Olatec Therapeutics Tech Stack
A closer look at the technologies used by Olatec Therapeutics
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Olatec Therapeutics
Sign Up For FreeTo access detailed company insights
Olatec is a privately held biopharmaceutical company focused on the clinical development of NLRP3 antagonist therapeutics aimed at treating a wide range of inflammatory diseases, including arthritis, heart failure, and various cancers. Their lead compound, dapansutrile, has shown clinical benefits in reducing systemic inflammation and has a favorab... Read More